» Articles » PMID: 35289038

Heart Failure Quality of Care and In-hospital Outcomes During the COVID-19 Pandemic: Findings from the Get With The Guidelines-Heart Failure Registry

Abstract

Aims: To assess heart failure (HF) in-hospital quality of care and outcomes before and during the COVID-19 pandemic.

Methods And Results: Patients hospitalized for HF with ejection fraction (EF) <40% in the American Heart Association Get With The Guidelines©-HF (GWTG-HF) registry during the COVID-19 pandemic (3/1/2020-4/1/2021) and pre-pandemic (2/1/2019-2/29/2020) periods were included. Adherence to HF process of care measures, in-hospital mortality, and length of stay (LOS) were compared in pre-pandemic vs. pandemic periods and in patients with vs. without COVID-19. Overall, 42 004 pre-pandemic and 37 027 pandemic period patients (median age 68, 33% women, 58% White) were included without observed differences across clinical characteristics, comorbidities, vital signs, or EF. Utilization of guideline-directed medical therapy at discharge was comparable across both periods, with rates of implantable cardioverter defibrillator (ICD) placement or prescription lower during the pandemic (vs. pre-pandemic period). In-hospital mortality (3.0% vs. 2.5%, p <0.0001) and LOS (mean 5.7 vs. 5.4 days, p <0.0004) were higher during the pandemic vs. pre-pandemic. The highest in-hospital mortality during the pandemic was observed among patients hospitalized in the Northeast region (3.4%). Among patients concurrently diagnosed with COVID-19 (n = 549; 1.5%), adherence to ICD placement or prescription, prescription of aldosterone antagonist or angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor at discharge were lower, and in-hospital mortality (8.2% vs. 3.0%, p <0.0001) and LOS (mean 7.7 vs. 5.7 days, p <0.0001) were higher than those without COVID-19.

Conclusion: Among GWTG-HF participating hospitals, patients hospitalized for HF with reduced EF during the pandemic received similar care quality but experienced higher in-hospital mortality than the pre-pandemic period.

Citing Articles

Angiotensin Receptor-Neprilysin Inhibitor Prescribing Patterns in Patients Hospitalized for Heart Failure.

Srivastava P, Klomhaus A, Greene S, Heidenreich P, Lewsey S, Yancy C JAMA Cardiol. 2024; 10(3):276-283.

PMID: 39661383 PMC: 11904728. DOI: 10.1001/jamacardio.2024.3815.


Angiotensin receptor-neprilysin inhibitor adherence and outcomes in heart failure with reduced ejection fraction.

Cho D, Choi J, Youn J, Kim M, Lee C, Son J ESC Heart Fail. 2024; 12(1):603-612.

PMID: 39420468 PMC: 11769608. DOI: 10.1002/ehf2.15117.


Guideline-directed medical therapy prescribing patterns and in-hospital outcomes among heart failure patients during COVID-19.

Srivastava P, Klomhaus A, Rafique A, Desai P, Daniels L, Yancy C Am Heart J Plus. 2024; 45:100440.

PMID: 39220717 PMC: 11363726. DOI: 10.1016/j.ahjo.2024.100440.


Excess cardiovascular mortality across multiple COVID-19 waves in the United States from March 2020 to March 2022.

Han L, Zhao S, Li S, Gu S, Deng X, Yang L Nat Cardiovasc Res. 2024; 2(3):322-333.

PMID: 39195997 DOI: 10.1038/s44161-023-00220-2.


Prioritizing the primary prevention of heart failure: Measuring, modifying and monitoring risk.

Patel R, Peesay T, Krishnan V, Wilcox J, Wilsbacher L, Khan S Prog Cardiovasc Dis. 2024; 82():2-14.

PMID: 38272339 PMC: 10947831. DOI: 10.1016/j.pcad.2024.01.001.


References
1.
Auerbach A, OLeary K, Greysen S, Harrison J, Kripalani S, Ruhnke G . Hospital Ward Adaptation During the COVID-19 Pandemic: A National Survey of Academic Medical Centers. J Hosp Med. 2020; 15(8):483-488. PMC: 7518133. DOI: 10.12788/jhm.3476. View

2.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

3.
Mehra M, Ruschitzka F . COVID-19 Illness and Heart Failure: A Missing Link?. JACC Heart Fail. 2020; 8(6):512-514. PMC: 7151428. DOI: 10.1016/j.jchf.2020.03.004. View

4.
Tomasoni D, Italia L, Adamo M, Inciardi R, Lombardi C, Solomon S . COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail. 2020; 22(6):957-966. PMC: 7273093. DOI: 10.1002/ejhf.1871. View

5.
Rey J, Caro-Codon J, Rosillo S, Iniesta A, Castrejon-Castrejon S, Marco-Clement I . Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail. 2020; 22(12):2205-2215. PMC: 7461427. DOI: 10.1002/ejhf.1990. View